Stockreport

Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Cogent Biosciences, Inc.  (COGT) 
Last cogent biosciences, inc. earnings: 11/8 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.cogint.com/investor-relations
PDF •   Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025 •   Plan to report top-line results from pivotal PEAK [Read more]